Ionis Pharmaceuticals’ Tryngolza is now the first approved therapy for treating severe hypertriglyceridemia, a prevalent chronic metabolic disorder that can lead to acute pancreatitis. This drug is a key piece of Ionis’s pivot away from partnering its assets, and instead developing and commercializing them on its own.
The post A Metabolic Disease Posing Severe Pancreatic Risks Gets Its First FDA-Approved Therapy appeared first on MedCity News.
